# US 2024/0285734 A1 · Gne as a therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0285734 A1
- Document ID: US20240285734A1
- Status: Published application
- Kind: A1
- Application number: 18/518,270
- Filed: 2024-05-14
- Published: 2024-08-29
- Earliest claimed: 2018-09-18
- Inventors: Daniel Darvish
- Web page: https://patentgrep.com/patent/US20240285734A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/45: Transferases (2)
- A61K 38/52: Isomerases (5)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/86: Viral vectors
- C12Y 207/0106: N-Acylmannosamine kinase (2.7.1.60)
- C12Y 302/01183: UDP-N-acetylglucosamine 2-epimerase (hydrolysing) (3.2.1.183)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to composition and methods for expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) in a living organism. In preferred embodiments, the invention relates to treating disease condition that involves use of therapeutically effective amount of a composition described herein.

## Claims

### Claim 1

A method of treating a subject, the method comprising:
administering to the subject a pharmaceutical composition comprising a recombinant vector comprising a DNA molecule encoding GNE or a therapeutic fragment thereof,
wherein the recombinant vector has a capsid comprising amino acid residues corresponding to Asp-271, Asn-272, Tyr-446, Asn-470, and Trp-503, as described in SEQ ID NO: 19 as Asp-1, Asn-2, Tyr-176, Asn-200, and Trp-233, thereby directing entry of the AAV vector into cells of the subject without a need for sialic on the cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered intravenously.

### Claim 3 (depends on 1)

The method of claim 1, wherein subsequent to the administration of the pharmaceutical composition, the subject experiences an increase in sialic content or sialylation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has at least one mutation in the gene encoding GNE.

### Claim 5 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to a limb or limbs of the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein subsequent to the administration of the pharmaceutical composition, the subject experiences an improvement in muscle function.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by hydrodynamic infusion.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition has a net negative charge.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a muscle specific promoter.

### Claim 10

A pharmaceutical composition comprising:
a recombinant vector comprising a DNA molecule encoding GNE or a therapeutic fragment thereof,
wherein the recombinant vector has a capsid comprising amino acid residues corresponding to Asp-271, Asn-272, Tyr-446, Asn-470, and Trp-503, as described in SEQ ID NO: 19 as Asp-1, Asn-2, Tyr-176, Asn-200, and Trp-233, thereby directing entry of the AAV vector into cells of the subject without a need for sialic on the cells.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition has a net negative charge.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises at least an eukaryotic enhancer.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises a muscle specific promoter.

### Claim 14 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises minimal prokaryotic or bacterial genome sequences.

### Claim 15 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises a heat inducible Mini-origin replication that enables high yield manufacturing of the recombinant vector.

### Claim 16

A pharmaceutical composition comprising:
a DNA molecule encoding GNE or a therapeutic fragment thereof, and containing at least one mutation or variation within an allosteric domain of GNE,
wherein the pharmaceutical composition comprises: (i) a net negative charge, (ii) an eukaryotic enhancer, and (iii) a pharmaceutically-acceptable carrier, adjuvant, or vehicle.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, further comprising a recombinant vector.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, further comprising minimal prokaryotic or bacterial genome sequences.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the pharmaceutical composition comprises a muscle specific promoter.

### Claim 20 (depends on 16)

The pharmaceutical composition of claim 16, further comprising serine-arginine rich protein binding site.
